This phase II trial studies how well stereotactic body radiation therapy with HyperArc software technology works in treating patients with head and neck cancer that has come back (recurrent). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03892720.
PRIMARY OBJECTIVE:
I. To evaluate the safety and feasibility of using HyperArc for head and neck targets.
II. To evaluate local control and toxicity of patients who receive escalated dose stereotactic body radiation therapy (SBRT) reirradiation with HyperArc for recurrent head and neck cancer (rHNC).
SECONDARY OBJECTIVE:
I. To evaluate the clinical benefit of HyperArc through the analysis of overall survival (OS), progression-free survival (PFS) and locoregional progression-free survival (LPFS).
EXPLORATORY OBJECTIVE:
I. To evaluate dosimetric data including dose to target and organs at risk (OAR).
II. Buccals deoxyribonucleic acid (DNA) markers predictive of response and/or toxicity.
OUTLINE:
Patients undergo treatment planning with both standard radiation treatment software and HyperArc software technology. The most optimal plan (selected based on the discretion of the treating radiation oncologist) will be delivered to a total dose of 55 Gy in 5 fractions, given 2-3 times weekly over a 2-week period.
After completion of study treatment, patients are followed up at 1, 3, 6, 9, and 12 months.
Lead OrganizationUCLA / Jonsson Comprehensive Cancer Center
Principal InvestigatorRobert Kaida Chin
